• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 3 filed by new insider Ferge Kristin A

    3/15/24 6:46:55 PM ET
    $NRXS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $NRXS alert in real time by email
    SEC FORM 3 SEC Form 3
    FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0104
    Estimated average burden
    hours per response: 0.5
    1. Name and Address of Reporting Person*
    Ferge Kristin A

    (Last) (First) (Middle)
    C/O NEURAXIS, INC.
    11611 N. MERIDIAN STREET, SUITE 330

    (Street)
    CARMEL IN 46032

    (City) (State) (Zip)
    2. Date of Event Requiring Statement (Month/Day/Year)
    03/07/2024
    3. Issuer Name and Ticker or Trading Symbol
    Neuraxis, INC [ NRXS ]
    4. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    5. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Beneficially Owned
    1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
    Table II - Derivative Securities Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
    Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    No securities are beneficially owned.
    /s/ Kristin Ferge 03/15/2024
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $NRXS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $NRXS

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $NRXS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Hannasch Brian bought $31,251 worth of shares (18,065 units at $1.73), increasing direct ownership by 2% to 775,966 units (SEC Form 4)

      4 - Neuraxis, INC (0001933567) (Issuer)

      4/23/25 4:38:50 PM ET
      $NRXS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $NRXS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Hannasch Brian bought $31,251 worth of shares (18,065 units at $1.73), increasing direct ownership by 2% to 775,966 units (SEC Form 4)

      4 - Neuraxis, INC (0001933567) (Issuer)

      4/23/25 4:38:50 PM ET
      $NRXS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form 3 filed by new insider Aharon Gil

      3 - Neuraxis, INC (0001933567) (Issuer)

      11/26/24 3:57:02 PM ET
      $NRXS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Director Ferge Kristin A was granted 1,183 shares (SEC Form 4)

      4 - Neuraxis, INC (0001933567) (Issuer)

      7/2/24 3:18:16 PM ET
      $NRXS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $NRXS
    Financials

    Live finance-specific insights

    See more
    • NeurAxis Reports Strong First Quarter 2025 Financial Results Driven by a 39% Growth in Revenues

      CARMEL, Ind., May 12, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. ("NeurAxis," or the "Company") (NYSE:NRXS), a medical technology company commercializing neuromodulation therapies for chronic and debilitating conditions in children and adults, today announced results for the first quarter 2025 for the period ended March 31, 2025. 1Q25 Financial highlights Revenues increased 39% year over year to $896 thousand in 1Q25 compared to $647 thousand in 1Q24.Revenues increased 18% quarter over quarter to $896 thousand in 1Q25 compared to $761 thousand in 4Q24.Operating loss (excluding a one-time legal settlement) improved by 9% compared to the first quarter of 2024.Cash balance was $2.0 million as

      5/12/25 8:15:00 AM ET
      $NRXS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • NeurAxis to Host First Quarter 2025 Results and Business Update Call on Monday, May 12, 2025

      CARMEL, Ind., May 05, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. ("NeurAxis," or the "Company") (NYSE:NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults, will report financial results for its first quarter 2025, for the period ended March 31, 2025, on Monday, May 12, 2025, before market open. The Company has scheduled a conference call for the same day, Monday, May 12, 2025, at 9:00 am ET to review the results. Conference Call Details Date and Time: Monday, May 12, 2024, at 9:00am ET Live Webcast Information: Interested parties can access the conference call via a live webcast, which is availab

      5/5/25 9:00:00 AM ET
      $NRXS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • NeurAxis Reports Strong Fourth Quarter 2024 Financial Results Driven by a 43% Increase in Revenues

      CARMEL, Ind., March 20, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. ("NeurAxis," or the "Company") (NYSE:NRXS), a medical technology company commercializing neuromodulation therapies for chronic and debilitating conditions in children and adults, today announced results for the fourth quarter and fiscal year 2024 for the period ended December 31, 2024. 4Q24 Financial highlights Revenues increased 43% to $761 thousand in 4Q24 compared to $531 thousand in 4Q23.Operating loss improved by 10% compared to the fourth quarter of 2023.Cash balance was $3.7 million as of December 31, 2024. Recent Operational Highlights Expanded total covered lives to approximately 51 million compared to 4 million a

      3/20/25 8:15:00 AM ET
      $NRXS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $NRXS
    Leadership Updates

    Live Leadership Updates

    See more
    • NeurAxis Appoints Timothy Henrichs as Chief Financial Officer

      CARMEL, Ind., Jan. 31, 2024 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (NYSE American: NRXS) ("NeurAxis" or the "Company"), a medical technology company commercializing neuromodulation therapies that address chronic and debilitating conditions in children and adults, today announced the appointment of Timothy Henrichs as Chief Financial Officer (CFO), effective February 5, 2024. As part of his appointment, Mr. Henrichs has resigned as an independent director on the board of NeurAxis (the "Board"). "We are thrilled to announce Tim as the new Chief Financial Officer of NeurAxis," said Brian Carrico, President and Chief Executive Officer of NeurAxis. "His extensive experience will be highly valuable

      1/31/24 9:00:00 AM ET
      $NRXS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $NRXS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D filed by Neuraxis Inc.

      SC 13D - Neuraxis, INC (0001933567) (Subject)

      12/2/24 11:53:07 AM ET
      $NRXS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form SC 13G filed by Neuraxis Inc.

      SC 13G - Neuraxis, INC (0001933567) (Subject)

      12/2/24 9:57:28 AM ET
      $NRXS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Neuraxis Inc.

      SC 13G/A - Neuraxis, INC (0001933567) (Subject)

      10/8/24 7:30:11 AM ET
      $NRXS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $NRXS
    SEC Filings

    See more
    • SEC Form 8-K filed by Neuraxis Inc.

      8-K - Neuraxis, INC (0001933567) (Filer)

      5/22/25 6:45:22 AM ET
      $NRXS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form 424B5 filed by Neuraxis Inc.

      424B5 - Neuraxis, INC (0001933567) (Filer)

      5/22/25 6:30:45 AM ET
      $NRXS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Neuraxis Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Other Events, Financial Statements and Exhibits

      8-K - Neuraxis, INC (0001933567) (Filer)

      5/21/25 5:25:26 PM ET
      $NRXS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $NRXS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • NeurAxis Announces Closing of $5.0 Million Registered Direct Offering

      CARMEL, Ind., May 22, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. ("NeurAxis," or the "Company") (NYSE:NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults, today announced the closing of its previously announced registered direct offering of 1,538,461 shares of its common stock at a purchase price of $3.25 per share. The gross proceeds from the offering are approximately $5.0 million, before deducting placement agent fees and other offering expenses. "This financing, along with the recent FDA clearance expanding indications for IB-Stim treatment of Pediatric Functional Abdominal Pain (FAP), marks a

      5/22/25 1:03:01 PM ET
      $NRXS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • NeurAxis Announces $5.0 Million Registered Direct Offering

      CARMEL, Ind., May 21, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. ("NeurAxis," or the "Company") (NYSE:NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults, today announced that it has entered into definitive agreements for the purchase and sale of an aggregate of 1,538,461 shares of its common stock at a purchase price of $3.25 per share in a registered direct offering priced at the market under NYSE American rules. The offering is expected to close on or about May 22, 2025, subject to the satisfaction of customary closing conditions. Craig-Hallum Capital Group is acting as the exclusive place

      5/21/25 7:00:00 AM ET
      $NRXS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • NeurAxis Awarded First Ever FDA Clearance for the Treatment of Pediatric FAP/Functional Dyspepsia (FD) and Associated Nausea Symptoms

      •   Significantly expands IB-Stim's total addressable market •   Clearance covers patients aged 8–21 •   Seamless go-to-market strategy with existing reimbursement and provider infrastructure CARMEL, Ind., May 20, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. ("NeurAxis," or the "Company") (NYSE:NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults, today announced that it has received FDA 510(k) clearance for IB-Stim™ for the treatment of Pediatric Functional Abdominal Pain (FAP) associated with Functional Dyspepsia, and FD related Nausea Symptoms, in patients aged 8 to 21 years. This clearance is t

      5/20/25 8:00:00 AM ET
      $NRXS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care